Investing in the New Future of Cancer Therapy
TILT Biotherapeutics (Tiltbio) is the world’s leading company developing investigational oncolytic immunotherapies to enable T-cell therapy of solid tumors, with ovarian cancer as the lead indication.
Tiltbio offers an innovative investment opportunity that supports transforming the standard of care for advanced solid cancer tumor treatment.
The company’s strong intellectual property, a proprietary platform called TILT® technology, is based on decades of biotech and oncology treatment and research experience by founding CEO, Akseli Hemminki, M.D., PhD., and a highly regarded team of experienced industry professionals.
Tiltbio’s clinical development roadmap includes multiple promising products in its pipeline and collaboration with industry-leading pharmaceutical companies like Merck & Co. and Merck KGgA
The company’s lead candidate, TILT-123 (igrelimogene Iitadenorepvec) shows systemic effects in advanced solid tumors. Several Phase I studies have been completed with excellent safety profile so far. In a Phase Ia study in 15 ovarian cancer patients, disease control was achieved in 64% of patients. TILT-123 is now in Phase II for ovarian cancer.
Our Funding
TILT Biotherapeutics was formed in 2013 and has secured more than 70 M€ of funding (about 75% from equity and the rest in non-dilutive funding) from investors that include:
- European Innovation Council (EIC Fund)
- Lifeline Ventures
- Finnish Industry Investment Ltd (Tesi)
- Stephen Industries Inc Ltd.
- Growth investment firm Springvest Oyj and Finnish private investors
- Business Finland
- U.S. Department of Defence
The latest equity investment round was completed in March 2025. This Series B funding is used mainly for Phase Ib/II development of TILT-123.
For more information on investing in Tiltbio, please contact bd@tiltbio.com.